| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H35N3O |
| Molecular Weight | 393.5649 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)N1C=C2C[C@@H]3[C@H](C[C@H](CN3C)C(=O)NC4CCCCC4)C5=CC=CC1=C25
InChI
InChIKey=KEMOOQHMCGCZKH-JMUQELJHSA-N
InChI=1S/C25H35N3O/c1-16(2)28-15-17-13-23-21(20-10-7-11-22(28)24(17)20)12-18(14-27(23)3)25(29)26-19-8-5-4-6-9-19/h7,10-11,15-16,18-19,21,23H,4-6,8-9,12-14H2,1-3H3,(H,26,29)/t18-,21-,23-/m1/s1
| Molecular Formula | C25H35N3O |
| Molecular Weight | 393.5649 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Amesergide (previously known as LY237733) an ergoline derivative with highly selective 5-hydroxytryptamine (5-HT) antagonist activity and with a long duration of action. This drug was in phase II clinical trials for the treatment of erectile dysfunction and for the treatment of premature ejaculation. In addition, this drug participated in preclinical experiments to treat depression. All these studies were discontinued.
